Tezosentan in Pulmonary Arterial Hypertension
Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines
Sponsor: Idorsia Pharmaceuticals Ltd.
Terminated
Due to slow recruitment, the study was prematurely discontinued
Other terminated trials from Idorsia Pharmaceuticals Ltd.
- Healthy · Phase PHASE1 · Apr 2021
- Healthy Subjects · Phase PHASE1 · Dec 2017
- Pulmonary Arterial Hypertension · Phase PHASE2 · Sep 2011
- Aneurysmal Subarachnoid Hemorrhage · Phase PHASE3 · Jan 2011
- Heart Diseases · Phase PHASE3 · Mar 2008
More terminations from Idorsia Pharmaceuticals Ltd.
Other Pulmonary Arterial Hypertension trials with similar outcome
This PHASE2 trial investigates Pulmonary Arterial Hypertension and is currently terminated or withdrawn. Idorsia Pharmaceuticals Ltd. leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Aug 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Idorsia Pharmaceuticals Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .